Moderna Named a Top Employer by Science for Seventh Consecutive Year - Seite 2
Moderna has continued to prioritize employee well-being, even as new COVID-19 variants and other pipeline advancements drove urgency of innovation across the organization. The Company is committed to maintaining an inclusive culture and instituted a Conscious Inclusion diversity training series, hosted learning opportunities and celebrations to encourage dialogue through diversity-related events and doubled the number of its Employee Resource Groups, from three to six, with two more in the early stages of forming. At its annual R&D Day, Moderna unveiled plans to reinvigorate employee training and development programs, with a particular focus on AI Academy, as well as outlined how it has prioritized accelerating digital investments over the past year to better support employee collaboration and co-invention.
“Over the past ten years, we brought together the curious, the bold and the visionaries to advance mRNA science for society and create a COVID-19 vaccine,” said Tracey Franklin, Chief Human Resources Officer. “Together, we demonstrated that when you put humans in the right environment and allow them to be who they are, they will achieve incredible things.”
The annual survey’s findings are based on more than 7,200 completed surveys from readers of Science and other survey invitees. Survey respondents came from North America (64%), Europe (19%), and Asia/Pacific Rim (11%); 95% worked in biotechnology, biopharmaceutical, and pharmaceutical companies. The responses were analyzed by The Brighton Consulting Group, which used a mathematical process to determine the driving characteristics of a top employer and to assign a unique score to rate each company’s employer reputation.
For the complete feature along with individual company rankings, please visit: https://www.sciencecareers.org/TopEmployers2021.
About Moderna
Lesen Sie auch
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most effective vaccines against the COVID-19 pandemic.